Compare PDLB & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDLB | CRDF |
|---|---|---|
| Founded | 1960 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 405.9M | 142.1M |
| IPO Year | 2017 | N/A |
| Metric | PDLB | CRDF |
|---|---|---|
| Price | $16.88 | $3.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.63 |
| AVG Volume (30 Days) | 105.5K | ★ 1.0M |
| Earning Date | 01-27-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.83 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $96,252,000.00 | $501,000.00 |
| Revenue This Year | $10.97 | N/A |
| Revenue Next Year | $8.59 | N/A |
| P/E Ratio | $19.00 | ★ N/A |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $10.88 | $1.90 |
| 52 Week High | $18.01 | $4.99 |
| Indicator | PDLB | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 60.81 | 80.94 |
| Support Level | $16.87 | $2.32 |
| Resistance Level | $17.48 | $2.95 |
| Average True Range (ATR) | 0.43 | 0.17 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 53.81 | 94.78 |
Ponce Financial Group Inc, is a United States-based holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in mortgage loans, consisting of one-to-four-family residential, multi-family residential, non-residential property and construction and land, and, to a lesser extent, business, and consumer loans. The company also invests in securities, which consists of securities issued by the U.S. Government and federal agencies and mortgage-backed securities issued by the United States government-sponsored enterprises. Some of the products and services include checking solutions, online and mobile banking, merchant credit card services, and others.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.